STOCK TITAN

Sensei Biotherapeutics (SNSE) awards director 12,500 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Sensei Biotherapeutics director Bob Holmen received a grant of stock options for 12,500 shares of Common Stock. The options have an exercise price of $11.41 per share and expire on June 9, 2036. They vest in 12 equal monthly installments over one year, becoming fully vested on June 10, 2027, subject to his continuous service. Following this award, he holds 12,500 options directly.

Positive

  • None.

Negative

  • None.
Insider Holmen Bob
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 12,500 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 12,500 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 12,500 options Grant to director Bob Holmen on June 10, 2026
Exercise price $11.41 per share Stock Option (right to buy) for Common Stock
Underlying shares 12,500 shares Common Stock underlying the options granted
Expiration date June 9, 2036 Option expiration for this grant
Post-grant holdings 12,500 options Total options held following the transaction
Vesting schedule 12 monthly installments over 1 year Fully vested on June 10, 2027, subject to service
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 11.4100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to the option vest and become exercisable in 12 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
expiration date financial
"expiration_date: 2036-06-09T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Sensei Biotherapeutics (SNSE) director Bob Holmen report on this Form 4?

He reported receiving a grant of 12,500 stock options. These options give him the right to buy Sensei Biotherapeutics Common Stock at a preset price, reflecting part of his equity-based director compensation package.

How many Sensei Biotherapeutics (SNSE) options were granted to Bob Holmen and at what price?

He was granted 12,500 stock options with an exercise price of $11.41 per share. This price is what he must pay per share if he later chooses to exercise the options for Common Stock.

When do Bob Holmen’s Sensei Biotherapeutics (SNSE) options vest?

The 12,500 options vest in 12 equal monthly installments over one year. They become fully vested on June 10, 2027, provided he continues serving with Sensei Biotherapeutics through each monthly vesting date.

When do the Sensei Biotherapeutics (SNSE) options granted to Bob Holmen expire?

These stock options expire on June 9, 2036. After that expiration date, any unexercised options become worthless, so exercise must occur before then if he chooses to purchase the underlying shares.

Is Bob Holmen’s Form 4 for Sensei Biotherapeutics (SNSE) a purchase or a grant?

It is a grant of stock options classified as an acquisition. The transaction code is “A,” indicating a grant, award, or other acquisition rather than an open-market stock purchase or sale.

How many Sensei Biotherapeutics (SNSE) options does Bob Holmen hold after this transaction?

After the grant, he directly holds 12,500 stock options. These options relate to 12,500 underlying shares of Common Stock, subject to the disclosed vesting schedule and the June 2036 expiration date.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Holmen Bob

(Last)(First)(Middle)
C/O SENSEI BIOTHERAPEUTICS, INC.
1405 RESEARCH BLVD, SUITE 125

(Street)
ROCKVILLE MARYLAND 20850

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ SNSE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$11.4106/10/2026A(1)12,500 (1)06/09/2036Common Stock12,500$012,500D
Explanation of Responses:
1. The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Josiah Craver, Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)